254. ポルフィリン症 [臨床試験数:34,薬物数:35(DrugBank:20),標的遺伝子数:17,標的パスウェイ数:30]
Searched query = "Porphyria", "Hereditary coproporphyria", "Erythropoietic protoporphyria", "X linked dominant protoporphyria"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04056481 | August 20, 2019 | 11 November 2019 | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria | Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria (AHP) | Acute Hepatic Porphyria | Drug: Givosiran | Alnylam Pharmaceuticals | Not recruiting | 12 Years | N/A | All | Phase 2 | United States;France | ||
2 | NCT03520036 | July 5, 2018 | 4 November 2019 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria (EPP) | Drug: MT-7117 low dose;Drug: MT-7117 high dose;Drug: Placebo | Mitsubishi Tanabe Pharma Development America, Inc. | Not recruiting | 18 Years | 75 Years | All | 102 | Phase 2 | United States | |
3 | NCT03505853 | April 26, 2018 | 25 March 2019 | A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP) | A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE) | Acute Intermittent Porphyria (AIP);Acute Hepatic Porphyria (AHP);Porphyria, Acute Intermittent;Acute Porphyria | Drug: Givosiran;Drug: 5-probe cocktail | Alnylam Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 10 | Phase 1 | Sweden | |
4 | EUCTR2017-002432-17-PL | 12/04/2018 | 28 February 2019 | Study on an Investigational Drug, Givosiran, for the Treatment of Acute Hepatic Porphyrias | ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias - ENVISION | Acute Hepatic Porphyrias (AHP) MedDRA version: 20.0 Level: PT Classification code 10036182 Term: Porphyria acute System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0 Level: LLT Classification code 10036184 Term: Porphyria hepatic System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Alnylam Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 74 | Phase 3 | United States;Taiwan;Finland;Spain;Italy;Switzerland;United Kingdom;France;Czech Republic;Mexico;Canada;Poland;Belgium;Brazil;Denmark;Australia;Bulgaria;Netherlands;Germany;Japan;Korea, Republic of;Sweden | |||
5 | EUCTR2016-002638-54-SE | 20/12/2017 | 20 August 2018 | Long-term Safety and Clinical Activity of ALN-AS1 in Patients with Acute Intermittent Porphyria (AIP), a rare metabolic disorder. | A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical Study with ALN-AS1 | Acute Intermittent Porphyria (AIP) MedDRA version: 20.0 Level: LLT Classification code 10000818 Term: Acute intermittent porphyria System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189- | Alnylam Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 24 | Phase 1;Phase 2 | United States;United Kingdom;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT03118674 | August 10, 2017 | 15 July 2019 | Harvoni Treatment Porphyria Cutanea Tarda | Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C | Porphyria Cutanea Tarda;Hepatitis C | Drug: Harvoni | Wake Forest University Health Sciences | Gilead Sciences;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH) | Recruiting | 18 Years | N/A | All | 49 | Phase 2 | United States |
7 | NCT02979249 | December 2016 | 26 August 2019 | Oral Iron for Erythropoietic Protoporphyrias | Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias | Erythropoietic Protoporphyria;EPP;X-linked Protoporphyria;XLP | Drug: Oral Iron | Icahn School of Medicine at Mount Sinai | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | All | 150 | N/A | United States |
8 | NCT02943213 | November 2016 | 16 December 2017 | Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride | A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions | Anti-Psychotic;Management of Manifestations of Psychotic Disorders;Treatment of Schizophrenia;Control Nausea and Vomiting;Relief of Restlessness and Apprehension Before Surgery;Acute Intermittent Porphyria;Adjunct in the Treatment of Tetanus;Control Manifestations of the Manic Type of Mani-depressive Illness;Relief of Intractable Hiccups | Drug: Chlorpromazine Hydrochloride | Cycle Pharmaceuticals Ltd. | Parexel | Not recruiting | 18 Years | 65 Years | All | 20 | Phase 1 | South Africa |
9 | NCT02949830 | October 2016 | 11 November 2019 | A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP) | A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1 | Acute Intermittent Porphyria | Drug: givosiran (ALN-AS1) | Alnylam Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 17 | Phase 1/Phase 2 | United States;Sweden;United Kingdom | |
10 | EUCTR2016-002638-54-GB | 30/08/2016 | 25 June 2018 | Long-term Safety and Clinical Activity of ALN-AS1 in Patients with Acute Intermittent Porphyria (AIP), a rare metabolic disorder. | A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed a Previous Clinical Study with ALN-AS1 | Acute Intermittent Porphyria (AIP) MedDRA version: 20.0 Level: LLT Classification code 10000818 Term: Acute intermittent porphyria System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Name: Givosiran Product Code: ALN-AS1 Pharmaceutical Form: Solution for injection INN or Proposed INN: ALN-60519 CAS Number: 1639325-44-2 Current Sponsor code: ALN-60519 Other descriptive name: CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 189- | Alnylam Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 24 | Phase 1;Phase 2 | United States;United Kingdom;Sweden | |||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
11 | NCT02922413 | October 30, 2015 | 2 September 2019 | Panhematin for Prevention of Acute Attacks of Porphyria | Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria | Acute Intermittent Porphyria;Hereditary Coproporphyria;Variegate Porphyria | Biological: Hemin for injection;Other: Placebo | The University of Texas Medical Branch, Galveston | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States | |
12 | NCT02452372 | May 6, 2015 | 25 June 2018 | A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) | A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP) | Acute Intermittent Porphyria | Drug: givosiran (ALN-AS1);Drug: Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 40 | Phase 1 | United States;Sweden;United Kingdom | |
13 | NCT02180412 | April 28, 2014 | 26 August 2019 | Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria | A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria | Acute Porphyrias | Biological: Panhematin;Other: Glucose | The University of Texas Medical Branch, Galveston | Not recruiting | 18 Years | 100 Years | All | 40 | Phase 2 | United States | |
14 | NCT02935400 | April 28, 2014 | 26 August 2019 | Acute Porphyria Biomarkers for Disease Activity | Acute Porphyrias: Biomarkers for Disease Activity and Response to Treatment | Acute Intermittent Porphyria;Hereditary Coproporphyria;Variegate Porphyria | Drug: Hemin | The University of Texas Medical Branch, Galveston | Not recruiting | 18 Years | N/A | All | 50 | Phase 3 | United States | |
15 | NCT01605136 | May 2012 | 30 September 2019 | Phase III Confirmatory Study in Erythropoietic Protoporphyria | A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | Drug: Afamelanotide;Drug: Placebo | Clinuvel Pharmaceuticals Limited | Not recruiting | 18 Years | N/A | All | 93 | Phase 3 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
16 | NCT01550705 | March 2012 | 19 October 2017 | Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria | Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria (EPP);X Linked Erythropoietic Protoporphyria | Drug: Isoniazid | University of Utah | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Icahn School of Medicine at Mount Sinai;University of Alabama at Birmingham;University of California, San Francisco;University of Texas | Not recruiting | 18 Years | N/A | All | 11 | N/A | United States |
17 | NCT01422915 | May 2011 | 16 December 2017 | Sorbent Therapy of the Cutaneous Porphyrias | Sorbent Therapy of the Cutaneous Porphyrias | Erythropoietic Protoporphyria | Drug: Colestipol | Brigham and Women's Hospital | Not recruiting | 22 Years | 60 Years | All | 4 | Phase 2/Phase 3 | United States | |
18 | NCT01284946 | January 2011 | 19 February 2015 | Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda | A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload | Porphyria Cutanea Tarda | Drug: Exjade | Assistance Publique - Hôpitaux de Paris | Association pour l'Etude des Fonctions Digestives (AEFD) | Recruiting | 18 Years | N/A | Both | 45 | Phase 2 | France |
19 | NCT01097044 | April 2010 | 19 February 2015 | Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP) | A Phase II, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | Drug: Afamelanotide;Drug: Placebo | Clinuvel Pharmaceuticals Limited | Not recruiting | 18 Years | N/A | Both | 77 | Phase 2 | United States | |
20 | NCT00979745 | September 2009 | 19 February 2015 | Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP) | A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | Drug: Afamelanotide;Drug: Placebo | Clinuvel Pharmaceuticals Limited | Not recruiting | 18 Years | 70 Years | Both | 70 | Phase 3 | Finland;France;Germany;Ireland;Netherlands;United Kingdom | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
21 | EUCTR2009-011018-51-NL | 06/08/2009 | 3 April 2012 | A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP). - Multicentre Phase III EPP Study 2 | A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP). - Multicentre Phase III EPP Study 2 | Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria | Product Name: afamelanotide Product Code: CUV1647 Pharmaceutical Form: Implant Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Subcutaneous use | Clinuvel Pharmaceuticals Limited | Not Recruiting | Female: yes Male: yes | 70 | Phase 3 | Finland;United Kingdom;Netherlands;Ireland | |||
22 | EUCTR2007-000636-13-GB | 17/06/2008 | 12 June 2012 | A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP Study | A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP) - Multicentre Phase III EPP Study | Erythropoietic Protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria | Product Name: CUV1647 Product Code: CUV1647 Pharmaceutical Form: Implant Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Subcutaneous use | Clinuvel Pharmaceuticals Limited | Authorised | Female: yes Male: yes | 80 | Phase 3 | Germany;United Kingdom;Netherlands;France;Italy;Sweden | |||
23 | NCT00599326 | January 2008 | 19 October 2017 | Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda | Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda | Porphyria Cutanea Tarda | Drug: Deferasirox | University of Texas Southwestern Medical Center | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 10 | Phase 3 | United States |
24 | EUCTR2007-002863-28-GB | 26/09/2007 | 26 November 2018 | Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001 | Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001 | Erythropoietic protoporphyria (EPP) MedDRA version: 9.1 Level: LLT Classification code 10015289 Term: Erythropoietic protoporphyria | Trade Name: Questran Product Name: Questran Pharmaceutical Form: Powder for oral suspension INN or Proposed INN: COLESTYRAMINE CAS Number: 11041126 Concentration unit: g gram(s) Concentration type: equal Concentration number: 4- | Guy's & St Thomas' NHS Foundation Trust | Not Recruiting | Female: yes Male: yes | 21 | Phase 4 | United Kingdom | |||
25 | NCT04053270 | May 2007 | 22 October 2019 | Multicentre Phase III Erythropoietic Protoporphyria Study | A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutanenous Bioresorbable CUV1647 Implants in Patients With Erythropoietic Protoporphyria (EPP) | Erythropoietic Protoporphyria | Drug: Afamelanotide;Drug: Placebo | Clinuvel Pharmaceuticals Limited | Not recruiting | 18 Years | 70 Years | All | 100 | Phase 3 | ||
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
26 | NCT01573754 | March 21, 2006 | 26 August 2019 | Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda | A Prospective Comparison of Low Dose Hydroxychloroquine and Phlebotomy in the Treatment of Porphyria Cutanea Tarda. IRB 02-435 | Porphyria Cutanea Tarda | Drug: Hydroxychloroquine;Procedure: Phlebotomy | The University of Texas Medical Branch, Galveston | Recruiting | 18 Years | 100 Years | All | 100 | Phase 2 | United States | |
27 | NCT00418795 | June 11, 2003 | 11 June 2018 | Porphozym in the Treatment of Acute Attacks in AIP | A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP | Acute Intermittent Porphyria | Drug: recombinant human porphobilinogen deaminase (Porphozym) | Zymenex A/S | Not recruiting | 18 Years | N/A | All | 36 | Phase 2/Phase 3 | United States | |
28 | NCT00004397 | January 1998 | 19 February 2015 | Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria | Porphyria | Drug: heme arginate;Drug: tin mesoporphyrin | National Center for Research Resources (NCRR) | University of Texas | Not recruiting | 18 Years | N/A | Both | 20 | Phase 1 | ||
29 | NCT00004398 | January 1998 | 19 February 2015 | Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria | Porphyria | Drug: heme arginate;Drug: tin mesoporphyrin | National Center for Research Resources (NCRR) | University of Texas | Not recruiting | 18 Years | N/A | Both | 24 | Phase 1 | ||
30 | NCT00004396 | September 1997 | 19 February 2015 | Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias | Porphyria | Drug: heme arginate;Drug: tin mesoporphyrin | National Center for Research Resources (NCRR) | University of Texas | Not recruiting | 18 Years | N/A | Both | 32 | Phase 2 | United States | |
No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
31 | NCT00004831 | October 1996 | 7 April 2015 | Study of Cysteine Hydrochloride for Erythropoietic Protoporphyria | Erythropoietic Protoporphyria | Drug: cysteine hydrochloride | FDA Office of Orphan Products Development | St. Luke's-Roosevelt Hospital Center | Not recruiting | 18 Years | 65 Years | Both | 20 | N/A | ||
32 | NCT00004940 | May 1996 | 7 April 2015 | Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria | Erythropoietic Protoporphyria | Drug: cysteine hydrochloride | Brigham and Women's Hospital | Not recruiting | 18 Years | 65 Years | Both | 50 | Phase 3 | |||
33 | NCT00004789 | July 1993 | 19 February 2015 | Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for Acute Porphyria | Porphyria | Drug: heme arginate;Drug: tin mesoporphyrin | National Center for Research Resources (NCRR) | University of Texas | Not recruiting | 18 Years | N/A | Both | 59 | Phase 1/Phase 2 | ||
34 | NCT00004330 | March 1987 | 19 February 2015 | Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks | Porphyria | Drug: luteinizing hormone-releasing factor | National Center for Research Resources (NCRR) | University of Texas | Not recruiting | 18 Years | 55 Years | Female | N/A | United States |